Late-stage pipeline Genmab maintains a strong late-stage clinical pipeline with wholly owned programs, presenting ongoing opportunities for additional collaborations, licensing, or co-development deals to expand its global reach and accelerate market access.

Darzalex momentum With substantial Darzalex and Tecvayli royalty growth and quarterly sales contributing to above-guidance potential, there is a clear opportunity to pursue partnerships around expansion into new indications, geographies, or combination therapies to maximize royalties.

Bispecific leadership Genmab’s leadership in antibody formats like bispecifics, including epcoritamab, suggests sales opportunities in collaborating on bispecific platforms, co-development, or licensing to broaden the company’s portfolio in hematology and oncology markets.

Global expansion Headquartered in Denmark with a strong presence across North America, Europe, and Asia Pacific, Genmab is well-positioned for cross-border partnerships, regional commercial rights, and market-entry collaborations to accelerate global growth.

Strategic collaborations Active collaborations with AbbVie and ongoing EPCORE trials indicate ripe opportunities for additional strategic alliances, milestone-driven arrangements, and leverage of Genmab’s R&D capabilities to de-risk and monetize late-stage assets.